NEKTAR THERAPEUTICS

NKTR
Real-time Estimate Quote. Real-time Estimate  - 10/28 02:30:22 pm
15.915USD -3.43%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 115147
EBITDA1 -427-467
Operating profit (EBIT)1 -440-492
Operating Margin -384%-334%
Pre-Tax Profit (EBT)1 -440-503
Net income1 -441-502
Net margin -384%-341%
EPS2 -2,52-2,83
Dividend per Share2 --
Last update 02/27/202009/24/2020
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 153-
Net Cash position1 -170
Leverage (Debt / EBITDA) -0,36x0,36x
Free Cash Flow1 -355-455
ROE (Net Profit / Equities) -28,2%-42,3%
Shareholders' equity1 1 5611 188
ROA (Net Profit / Asset) -21,4%-30,7%
Assets1 2 0641 638
Book Value Per Share2 7,965,68
Cash Flow per Share --
Capex1 26,320,4
Capex / Sales 22,9%13,9%
Last update 02/27/202010/28/2020
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 2 948 M $ -
Entreprise Value (EV) 2 779 M $ 2 902 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) -5,83x -6,39x
Capitalization / Revenue 20,0x 16,6x
EV / Revenue 18,9x 15,6x
EV / EBITDA -5,95x -7,43x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,90x 5,58x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) -334% -248%
Operating Leverage (Delta EBIT / Delta Sales) - 0,50x
Net Margin (Net Profit / Revenue) -341% -264%
ROA (Net Profit / Asset) -30,7% -45,2%
ROE (Net Profit / Equities) -42,3% -65,2%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   13,9% 12,4%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 11,1x 5,83x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend